Caterpillar Inc. (NYSE:CAT) declared a quarterly dividend. Shareholders of record on Tuesday, January 20th will be given a dividend of 0.70 per share on Friday, February 20th. This represents a $2.80 dividend on an annualized basis and a yield of 3.01%. Caterpillar Inc. (NYSE:CAT) in last trading activity fell -2.36% to close at $90.50. Company weekly performance is -8.38% while its quarterly performance stands at -13.04%. Caterpillar Inc. (NYSE:CAT) is -18.06% away from its 52 week high.
On 8 December The Dow Chemical Company (NYSE:DOW) signed definitive agreements to sell the company’s global sodium borohydride business to Vertellus Specialty Materials LLC and its polyolefin films plant in Findlay, Ohio, to Valfilm North America Inc., a wholly-owned subsidiary of VALGROUP Packaging Solutions. On last trading day The Dow Chemical Company (NYSE:DOW) fell -5.78% to close at $43.35. Its volatility for the week is 3.89% while volatility for the month is 2.69%. DOW’s sales growth for past 5 years was -0.10% and its EPS growth for past 5 years was 42.10%. The Dow Chemical Company (NYSE:DOW) monthly performance is -13.13%.
On 16 November Blue Nile Inc. (NASDAQ:NILE) has launched two exclusive engagement ring and fine jewelry collections from international fashion designer Zac Posen. On last trading day Blue Nile Inc. (NASDAQ:NILE) advanced 4.56% to close at $35.33. Its volatility for the week is 5.93% while volatility for the month is 4.07%. NILE’s sales growth for past 5 years was 8.80% and its EPS growth for past 5 years was 2.50%. Blue Nile Inc. (NASDAQ:NILE) monthly performance is -4.12%.
Zacks lowered shares of Harvard Bioscience Inc (NASDAQ:HBIO) from an outperform rating to a neutral rating in a research note issued to investors on Wednesday. Zacks currently has $5.40 price objective on the stock. Harvard Bioscience Inc. (NASDAQ:HBIO) has 4.70% insider ownership while its institutional ownership stands at 55.80%. In last trading activity company’s stock closed at $4.81.
On 2 December Ignyta, Inc. (NASDAQ:RXDX) announced that its San Diego diagnostic laboratory successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. The State of California inspector granted Ignyta permission to begin offering molecular diagnostic services to patients including those in the company’s clinical trials. On Friday shares of Ignyta, Inc. (NASDAQ:RXDX) closed at $6.75.